Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects
This study has been completed.
Sponsor:
Torrent Pharmaceuticals Limited
Information provided by:
Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier:
NCT00944346
First received: July 21, 2009
Last updated: July 22, 2009
Last verified: July 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objective:
- A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects.
Study Design:
- Randomized,single-dose,2-way crossover.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Metformin HCl |
Phase 1 |
| Study Type: | Interventional |
Resource links provided by NLM:
Further study details as provided by Torrent Pharmaceuticals Limited:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Subject is at least 18 years old.
- Subject had no clinically significant abnormal lab values at the screening evaluation.
- Subject's drugs of abuse, Hepatitis B, Hepatitis C, and HIV screenings were negative or non-relative.
- Acceptable screening of ECG.
- Female subject's pregnancy test at screening is negative.
- Subject had no evidence of underlying disease at the pre-entry physical examination.
- Subject has given written consent to participate.
- Female subject has not received any injectable or implantable contraceptive for a period of six months preceding this study.
- Agreed to undergo at least a 14-day pre-dose washout.
Beginning two weeks prior to dosing and throughout the study, female subject of childbearing potential agrees to utilize one of the following methods of contraception:
- Condom and topical spermicide
- Condom and diaphragm
- Intra-uterine device (I.U.D)
- Complete abstinence.
- Agree to abstain from consuming caffeine or alcohol for at least 48 hours. prior to study and throughout the blood collection periods.
Exclusion Criteria:
- History of treatment for alcoholism, substance abuse, or drug abuse with in the past 24 months.
- History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
- History of GRD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
- History of treatment for asthma, hypoxemia, dehydration, sepsis, metabolic acidosis and congestive heart failure.
- Subject is pregnant or lactating.
- History of drug hyper sensitivity.
- Subject was treated with any investigational drug during the four weeks prior to initial dosing for the study.
- Subject smokes more then 15 cigarettes per day or uses tobacco products or currently uses nicotine products.
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00944346 History of Changes |
| Other Study ID Numbers: | 40484 |
| Study First Received: | July 21, 2009 |
| Last Updated: | July 22, 2009 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013